Drug Trial Radar · NCT06590545
Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Jan 2025
Primary completion
Jan 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- David SimonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kyverna Therapeutics
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this phase I/II clinical trial is to investigate anti-CD 19 chimeric antigen receptor T cell (CAR-T cell) therapy in patients with antineutrophil cytoplasmic antibodies (ANCA) immunoglobulin (IgG) positive ANCA associated vasculitis (AAV). The main questions it aims to answer are: * To assess the safety of anti-CD19 CAR-T cell therapy in subjects with active, treatment refractory, ANCA-IgG-positive AAV * To assess the clinical efficacy of anti-CD19 CAR-T cell therapy in subjects with active, treatment refractory ANCA-IgG-positive AAV * To assess the ANCA seroconversion rate in subjects with active, treatment refractory ANCA-IgG-positive AAV Participants will receive a single dose of KYV-101 i.v., an autologous fully-human anti-CD19 CAR-T cell immunotherapy. Follow-up time is 52 weeks with regular visits at the site.
Conditions
- ANCA-IgG-positive ANCA Associated Vasculitis
Interventions
KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapyDrug
A dosage of 1x10\^8 KYV-101 CAR+ T cells will be administered intravenously as a single infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- number of subjects experiencing a cytokine release syndromeTime frame: Screening up to week 4
- antineutrophil cytoplasmic antibodies (ANCA) seroconversion rateTime frame: week 24
- adverse events and serious adverse events due to investigational medical productTime frame: up to 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.